Squarepoint’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.31M | Buy |
444,539
+53,940
| +14% | +$1.21M | 0.01% | 1115 |
|
|
2025
Q4 | $8.98M | Buy |
390,599
+256,827
| +192% | +$8.45M | 0.01% | 1130 |
|
|
2025
Q3 | $4.02M | Buy |
133,772
+112,089
| +517% | +$3.36M | ﹤0.01% | 1595 |
|
|
2025
Q2 | $788K | Sell |
21,683
-198,201
| -90% | -$7.15M | ﹤0.01% | 2875 |
|
|
2025
Q1 | $7.96M | Buy |
219,884
+131,895
| +150% | +$5.49M | 0.01% | 1136 |
|
|
2024
Q4 | $3.7M | Buy |
+87,989
| New | +$4.37M | ﹤0.01% | 1884 |
|
|
2024
Q3 | – | Sell |
-18,585
| Closed | -$764K | – | 4590 |
|
|
2024
Q2 | $764K | Sell |
18,585
-38,540
| -67% | -$1.65M | ﹤0.01% | 2755 |
|
|
2024
Q1 | $2.67M | Buy |
57,125
+41,284
| +261% | +$1.95M | ﹤0.01% | 1909 |
|
|
2023
Q4 | $758K | Buy |
+15,841
| New | +$614K | ﹤0.01% | 2721 |
|
|
2023
Q3 | – | Sell |
-11,558
| Closed | -$533K | – | 4154 |
|
|
2023
Q2 | $533K | Buy |
+11,558
| New | +$536K | ﹤0.01% | 2585 |
|
|
2023
Q1 | – | Sell |
-5,597
| Closed | -$259K | – | 3705 |
|
|
2022
Q4 | $259K | Sell |
5,597
-120,314
| -96% | -$4.73M | ﹤0.01% | 2650 |
|
|
2022
Q3 | $5.21M | Buy |
125,911
+73,806
| +142% | +$3.79M | 0.03% | 731 |
|
|
2022
Q2 | $3.11M | Buy |
52,105
+21,527
| +70% | +$1.32M | 0.02% | 934 |
|
|
2022
Q1 | $2.22M | Buy |
+30,578
| New | +$2.13M | 0.01% | 1095 |
|
|
2021
Q3 | – | Sell |
-67,005
| Closed | -$6.39M | – | 3338 |
|
|
2021
Q2 | $6.39M | Buy |
67,005
+63,355
| +1,736% | +$6.6M | 0.02% | 634 |
|
|
2021
Q1 | $416K | Buy |
+3,650
| New | +$497K | ﹤0.01% | 2156 |
|
|
2020
Q4 | – | Sell |
-33,537
| Closed | -$2.76M | – | 3199 |
|
|
2020
Q3 | $2.76M | Buy |
33,537
+26,663
| +388% | +$2.21M | 0.04% | 530 |
|
|
2020
Q2 | $538K | Sell |
6,874
-7,543
| -52% | -$499K | 0.01% | 1284 |
|
|
2020
Q1 | $641K | Sell |
14,417
-45,299
| -76% | -$2.35M | 0.02% | 908 |
|
|
2019
Q4 | $2.55M | Buy |
59,716
+49,020
| +458% | +$2.02M | 0.02% | 763 |
|
|
2019
Q3 | $458K | Buy |
10,696
+2,211
| +26% | +$120K | ﹤0.01% | 1663 |
|
|
2019
Q2 | $539K | Buy |
+8,485
| New | +$540K | 0.01% | 1616 |
|
|
2019
Q1 | – | Sell |
-32,253
| Closed | -$1.4M | – | 2388 |
|
|
2018
Q4 | $1.4M | Buy |
+32,253
| New | +$1.76M | 0.02% | 805 |
|
|
2017
Q4 | – | Sell |
-6,600
| Closed | -$352K | – | 2298 |
|
|
2017
Q3 | $352K | Buy |
+6,600
| New | +$391K | 0.01% | 1109 |
|
|
2017
Q2 | – | Sell |
-3,660
| Closed | -$248K | – | 1754 |
|
|
2017
Q1 | $248K | Buy |
3,660
+267
| +8% | +$20.3K | 0.01% | 1186 |
|
|
2016
Q4 | $239K | Sell |
3,393
-14,307
| -81% | -$1.02M | 0.01% | 1300 |
|
|
2016
Q3 | $1.26M | Buy |
17,700
+9,600
| +119% | +$613K | 0.08% | 289 |
|
|
2016
Q2 | $396K | Buy |
8,100
+2,452
| +43% | +$159K | 0.02% | 631 |
|
|
2016
Q1 | $358K | Buy |
5,648
+3,448
| +157% | +$226K | 0.03% | 753 |
|
|
2015
Q4 | $247K | Buy |
+2,200
| New | +$220K | 0.03% | 891 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Squarepoint's RARE Position: Q1 2026 in Review
Squarepoint increased its Ultragenyx Pharmaceutical (RARE) stake by 14% in Q1 2026, buying an estimated $1.21M and bringing the position to 444,539 shares worth $9.31M. The position accounts for 0.01% of the portfolio, ranked #1115.
Squarepoint first reported a position in RARE in Q4 2015 and has held it in 30 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Squarepoint held 444,539 shares of Ultragenyx Pharmaceutical worth $9.31M as of Q1 2026.
- Squarepoint bought 53,940 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $1.21M.
- Ultragenyx Pharmaceutical made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1115 holding.
- Squarepoint first reported a position in Ultragenyx Pharmaceutical in Q4 2015 and has held it in 30 quarters since.
- 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.